Sanofi CEO Paul Hudson’s suggestion that the US may get priority access to COVID-19 vaccines being developed by the Paris-headquartered company prompted a fury that highlights not just the tense geopolitics of the coronavirus era, but also the logistical hurdles that any successful development program will have to overcome in addition to the scientific challenges.
To wit, if you want a vaccine as fast as possible, you need to be willing to potentially waste a...







